AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved Imfinzi in 2017.

AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients. The company announced on Friday that the FDA had approved the ...

The guidance hike followed forecast-beating third quarter results, with revenues up 21% on a constant currency basis to 13.57 ...

Now, a newer option is available: an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...